Exicure to Participate in Upcoming Scientific Conferences
September 15 2021 - 7:00AM
Business Wire
Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
technology, today announced participation in the following
scientific conferences during the month of September:
TIDES USA 2021 Poster presentation: "Biodistribution of
Spherical Nucleic Acids in the Rat CNS Following ICM and IT
Delivery" September 20 – 30, 2021
17th Annual Meeting of the Oligonucleotide Therapeutics
Society Poster presentation: "Development of Spherical Nucleic
Acids Targeting FXN for the Treatment of Friedreich's Ataxia"
September 26 – 29, 2021
Posters will go live at the start of the conference and will be
available to conference attendees.
Exicure will add the posters to its website after each
conference.
About Exicure, Inc. Exicure, Inc. is a clinical-stage
biotechnology company developing therapeutics for neurology,
immuno-oncology, inflammatory diseases and other genetic disorders
based on its proprietary Spherical Nucleic Acid, or SNA technology.
Exicure believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN a
lipid-nanoparticle SNA–based therapeutic candidate, for the
intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s
therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2
clinical trial in patients with advanced solid tumors. Exicure is
based in Chicago, IL and in Cambridge, MA. www.exicuretx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210915005117/en/
Media Contact: Karen Sharma MacDougall 781-235-3060
ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024